Beijing Biostar Pharmaceuticals Co., Ltd. Class H (2563) Stock Statistics & Valuation Metrics

Beijing Biostar Pharmaceuticals Co., Ltd. Class H has a market cap or net worth of HK$1.28B. The enterprise value is HK$128.25M.

Beijing Biostar Pharmaceuticals Co., Ltd. Class H has 389,588,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -19.28%.

The current PE Ratio of Beijing Biostar Pharmaceuticals Co., Ltd. Class H is ―. Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s PEG ratio is 1.35.

In the last 12 months, Beijing Biostar Pharmaceuticals Co., Ltd. Class H had revenue of 37.12M and earned -142.54M in profits. Earnings per share was -0.39.

In the last 12 months, operating cash flow was -179.83M and capital expenditures -6.48M, giving a free cash flow of -186.30M billion.

Beijing Biostar Pharmaceuticals Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―

Beijing Biostar Pharmaceuticals Co., Ltd. Class H upcoming earnings date is Aug 26, 2026, Before Open (Not Confirmed).

Beijing Biostar Pharmaceuticals Co., Ltd. Class H as a current ratio of 8.33, with Debt / Equity ratio of 0.33%

In the past 12 months, Beijing Biostar Pharmaceuticals Co., Ltd. Class H has paid 0.00 in taxes.

Beijing Biostar Pharmaceuticals Co., Ltd. Class H EV to EBITDA ratio is -9.15, with an EV/FCF ratio of -7.33.

Beijing Biostar Pharmaceuticals Co., Ltd. Class H has HK$565.53M in cash and marketable securities with HK$2.45M in debt, giving a net cash position of HK$563.09M billion.

Gross margin is 92.12%, with operating margin of -407.86%, and net profit margin of -384.03%.

The average price target for Beijing Biostar Pharmaceuticals Co., Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―